IONS Q1 2023 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$131M-8.0% YoY

Gross Profit

$129M99.0% margin

Operating Income

-$114M-87.5% margin

Net Income

-$124M-95.2% margin

EPS (Diluted)

$-0.87

QoQ Revenue Growth

-14.1%

Cash Flow

Operating Cash Flow

-$134M

Free Cash Flow

-$146M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$2.4B

Stockholders' Equity

$487M

Cash & Equivalents

$309M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$142M	-8.0%
Gross Profit	$129M	$138M	-6.2%
Operating Income	-$114M	-$58M	-98.5%
Net Income	-$124M	-$65M	-90.8%

Revenue Segments

Commercial

$68M26%

Research and Development Revenue

$63M24%

Spinraza Royalties

$50M19%

Collaborative Agreement Revenue

$38M15%

Eplontersen Joint Development Revenue

$24M9%

Licensing and Other Royalties

$11M4%

Product

$6M2%